Skip to main content

Table 1 Patient and treatment characteristics

From: ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data

 

Total

ATM mut(−)

ATM mut(+)

p-value

N = 39

N = 29

N = 10

Median age [IQR], years

59.0 [47.5;63.0]

60.0 [52.0;64.0]

49.0 [37.0;59.0]

0.071

  < 60 years, n (%)

22 (56.4)

14 (48.3)

8 (80.0)

0.169

  ≥ 60 years, n (%)

17 (43.6)

15 (51.7)

2 (20.0)

 

Sex, n (%)

   

0.727

 Male

20 (51.3)

14 (48.3)

6 (60.0)

 

 Female

19 (48.7)

15 (51.7)

4 (40.0)

 

Preoperative KPS, n (%)

   

0.580

  ≤ 80

28 (71.8)

22 (75.9)

6 (60.0)

 

 90–100

11 (28.2)

7 (24.1)

4 (40.0)

 

Subventricular zone, n (%)

   

1.000

 Free

5 (12.8)

4 (13.8)

1 (10.0)

 

 Involvement

34 (87.2)

25 (86.2)

9 (90.0)

 

Gliomatosis, n (%)

   

0.515

 No

21 (53.8)

17 (58.6)

4 (40.0)

 

 Yes

18 (46.2)

12 (41.4)

6 (60.0)

 

Pathology*, n (%)

   

0.380

 Diffuse astrocytoma

2 (5.1)

2 (6.9)

0 (0.0)

 

 Anaplastic astrocytoma

10 (25.7)

6 (20.7)

4 (40.0)

 

 Glioblastoma

27 (69.2)

21 (72.4)

6 (60.0)

 

MGMT promoter, n (%)

   

1.000

 Unmethylated

15 (38.5)

11 (37.9)

4 (40.0)

 

 Methylated

24 (61.5)

18 (62.1)

6 (60.0)

 

Median Ki67 index [IQR], %

15.0 [6.5;26.2]

15.0 [6.5;27.5]

17.5 [7.5;30.0]

0.617

  < 15%, n (%)

16 (41.0)

12 (41.4)

4 (40.0)

1.000

  ≥ 15%, n (%)

23 (59.0)

17 (58.6)

6 (60.0)

 

Extent of resection, n (%)

   

0.562

 Biopsy

2 (5.1)

2 (6.9)

0 (0.0)

 

 Partial removal

18 (46.2)

14 (48.3)

4 (40.0)

 

 Subtotal removal

19 (48.7)

13 (44.8)

6 (60.0)

 

Median total RT dose [IQR], Gy

60.0 [60.0;60.0]

60.0 [60.0;60.0]

60.0 [60.0;60.0]

0.600

Median total RT fractions [IQR], fx

30.0 [30.0;30.0]

30.0 [30.0;30.0]

30.0 [30.0;30.0]

0.631

  1. Abbreviations: IQR interquartile range, ATM ataxia-telangiectasia mutated gene, mut mutation, KPS Karnofsky performance status, MGMT O[6]-methylguanine-DNA methyltransferase, RT radiation therapy, Gy gray, fx fractions
  2. * Pathology refers to the WHO grade